Articles related to KIDNEY DISEASE

A layered approach to care is described with lifestyle interventions being a key feature of the updated recommendations. The recommendations now include therapies proven to improve cardiovascular and kidney outcomes in patients with diabetes and CKD.

This trial including more than 6,500 patients randomized to empagliflozin or placebo and followed for a median of 2 years. Progression of kidney disease or death from cardiovascular causes was monitored over the course of the trial. Those outcomes occurred in approximately 13% of patients in the empagliflozin group versus approximately 17% of patients in the placebo group.

The association between lithium use and chronic kidney disease (CKD) has been unclear. This study showed that lithium over the long-term (i.e., 10 years) accelerated the decline in eGFR attributed to aging.

85-year-old woman with Hx of stage 3 chronic kidney disease New onset dyspnea and intermittent mild fever Slight difficulty opening her mouth; no dental caries or cervical lymphadenopathy Elevated CRP Elevated BUN Follow the case as it develops.

The founding editor of Comprehensive Clinical Nephrology teases out for us our physiologic response to salt, sugar, fat, and water that creates a recipe for obesity – a recipe being used daily by many Americans with obvious results. His recommendation? “Drinking more water and reducing salt intake offer cheap, easy and healthy strategies that may prevent or treat obesity.” Click to see the evidence behind the conclusion.

A newly developed prolyl hydroxylase inhibitor (agents that increase endogenous erythropoietin production) holds the promise of improving outcomes for patients with anemia of chronic kidney disease. Randomized controlled trials have found these drugs to be at least as effective as erythropoiesis-stimulating agents.